Perspectives
perspectives
April 8th, 2026
Four Pillars of My Success as a Clinical Trial Transparency Specialist
perspectives
March 25th, 2026
REMS and Labeling Are Strategic Design Decisions, Not Late-Stage Add-Ons
perspectives
March 12th, 2026
AI in Pharma: Autopilot Is Not the Same as Removing the Pilot
perspectives
March 3rd, 2026
Modeling and Simulation in Clinical Trials: A Practical Approach to De-Risking Study Design
perspectives
February 25th, 2026
Integrating AI and Automation Into Clinical Trial Operations With Discipline and Transparency
perspectives
February 10th, 2026
A Conversation with MMS Founder and CEO Dr. Uma Sharma: Building MMS: 20 Years of People-First, Data-Led Drug Development
perspectives
February 3rd, 2026
A Conversation with MMS Founder and CEO Dr. Uma Sharma: Building MMS: 20 Years of People-First, Data-Led Drug Development
perspectives
January 27th, 2026
What Regulators Want to See in Surrogate Endpoints Today
perspectives
January 20th, 2026
Behind the Scenes of Global Regulatory Submission Planning is a Symphony of Collaboration
perspectives
January 13th, 2026
Making Clinical Trial Technology Work in Practice
perspectives
December 16th, 2025
Inside Pharma and Biotech’s Shifting Landscape and the Direction Leaders Are Giving for 2026
perspectives
December 9th, 2025
The Real Meaning of “Expedited” in Drug Development